Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

Allergic Rhinitis Clinical Trial

— SIERRA  

Official title:

Phase III, Multicenter, Double-blind, Planned, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children Aged Between 6 and 11 Years

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06272409
• Other study ID #: DEP114-III-0123
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: February 15, 2025
• Est. completion date: April 15, 2027

Study information

• Verified date: February 2024
• Source: EMS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years.

Description:

- double-blind, superiority, parallel group trial. - Experiment duration: 05 days. - 03 visits (days 0, 5 and 28). - Efficacy will be evaluated for persistent allergic rhinitis based on Global improvement in nasal symptoms score - Adverse events evaluation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 318
• Est. completion date: April 15, 2027
• Est. primary completion date: March 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 11 Years

Eligibility

Inclusion Criteria:

• Ability to confirm voluntary participation and agree for all the purposes of the test, signing and dating the Term of Free and Informed Assent (TALE), signed by the Free and Informed Consent Form (TCLE) by responsible;
• Age = 6 years and = 11 years on the day of signing the TALE and the TCLE by the person responsible;
• Diagnosis of moderate to severe persistent allergic rhinitis (PAR) according to the criteria of Allergic Rhinitis and its Impact on Asthma (ARIA);
• Presence of sensitization to aeroallergens confirmed by positive result to the immediate reading skin test (PRICK test) and/or the presence of specific IgE to the test radioallergoabsorbent (RAST);
• Symptom intensity score "nasal obstruction" = 2 points.
• Total nasal symptoms score (TNSS) = 8 points.

Exclusion Criteria:

• Use of prednisolone or other oral or parenteral corticosteroid in the seven (07) days prior to inclusion;
• Use of H1 antihistamine, anti-leukotriene and decongestant topic in the seven (07) days prior to inclusion;
• Use or indication for the use of antibiotics at the screening visit and randomization;
• Presence of adenoid hypertrophy or anatomical disorders known obstructive disorders (e.g. septal deviation) that may be held responsible for nasal obstruction, at the discretion of the investigator;
• Diagnosis of severe or uncontrolled asthma;
• Allergy to desloratadine, prednisolone or any other component of the formulation of investigational products (PSIs);
• Presence of systemic fungal infection;
• Presence of any uncontrolled infection;
• Presence of any clinical observation finding (evaluation clinical/physical) or laboratory condition that is interpreted by the investigator physician as a risk to participation in the trial clinical or presence of serious uncontrolled disease(s);
• Participants who are pregnant or breastfeeding;
• Participation in clinical trial protocols in the last 12 (twelve) months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator believes that there may be direct benefit to the participant.

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

Intervention

Drug:
• DEP114
DEP114 oral solution
• Desloratadine 0.5 MG/ML
Desloratadine oral solution

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
EMS

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To demonstrate the superiority of DEP114 in relation to desloratadine 0.5 mg/mL in relieving the nasal symptoms of moderate to severe persistent allergic rhinitis in children, five days after starting treatment.	Global improvement in nasal symptoms (absolute variation in total nasal symptoms score obstruction, runny nose, itching and sneezing, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) five days after the start of treatment.	5 days
Secondary	To evaluate the effectiveness of DEP114 in relieving nasal symptoms of moderate to severe persistent allergic rhinitis in children, throughout the treatment.	Global improvement in nasal symptoms throughout treatment (absolute variation in the total score of nasal symptoms, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) on days 1, 2, 3, 4 and 5.; Improvement of nasal symptoms three days after the start of the treatment (proportion of participants with improvement in total nasal symptoms score, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) three days after the start of treatment, with improvement in total nasal symptoms score change of at least 4 points on day 3 compared to at baseline).	1-5 days
Secondary	Evaluate the efficacy of DEP114 to relieve nasal obstruction present in moderate to severe persistent allergic rhinitis in children through the treatment.	Improvement of nasal obstruction throughout treatment (absolute variation in total nasal symptoms score obstruction, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) on days 1, 2, 3, 4 and 5.	1-5 days
Secondary	Evaluate the efficacy of DEP114 to relieve coryza present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment.	Improvement of the runny nose three and five days after the start of the treatment (distribution of participants according to intensity of coryza at baseline, three and five days after the start of treatment).	3 and 5 day
Secondary	Evaluate the efficacy of DEP114 to relieve nasal itching present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment.	Improvement of nasal itching three and five days after the onset treatment (distribution of participants according to intensity of nasal itching at baseline, three and five days after starting treatment).	3 and 5 day
Secondary	Evaluate the efficacy of DEP114 to relieve sneezing present in persistent allergic rhinitis moderate to severe in children, three and five days after the start of treatment.	Improvement in sneezing three and five days after the start of the treatment (distribution of participants according to intensity of sneezing at baseline, three and five days after starting treatment).	3 and 5 day
Secondary	Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the perception of the person responsible for the participant.	Overall assessment of the treatment by the person responsible for the treatment participant five days after the start of treatment (distribution of participants according to a 5-point categorical scale, where 0=very bad, 1=bad, 2=neither good nor bad, 3=good, 4=very good).	5 day
Secondary	Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the investigator's perception.	Overall assessment of treatment by the investigator five days after the start of treatment (distribution of participants according to a 5-point categorical scale, where 0=very bad 1=bad, 2=neither good nor bad, 3=good, 4=very good).	5 day